Overview

Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus

Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label extension study designed to examine the long-term safety of pramlintide treatment in subjects with type 1 diabetes who have successfully completed treatment in the parent study 137-150.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Islet Amyloid Polypeptide
Pramlintide